New Therapy Demonstrated Promise During New Analysis of Clinical Studies

The director of clinical trials for the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas hailed as “great news” Tuesday’s announcement by the drug company Biogen that it would seek federal approval for a new drug to treat cognitive decline in Alzheimer’s patients.

“It’s a step in the right direction toward a therapy that may change the course of a disease that affects millions of Americans,” said Dr. Aaron Ritter, the principal investigator in a study of the drug conducted at the Ruvo Center. Read more.